We are live on ! Find out more
FPRX

Five Prime Therapeutics, Inc.
FPRX

Delisted

FPRX was delisted on the 15th of April, 2021.

Back to rankings

62 hedge funds and large institutions have $177M invested in Five Prime Therapeutics, Inc. in 2014 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 12 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 12

67% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 9

11% more funds holding

Funds holding: 56 → 62 (+6)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

18% less capital invested

Capital invested by funds: $215M → $177M (-$37.7M)

Holders
62
Holders Change
+6
Holders Change %
+10.71%
% of All Funds
1.78%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
15
Increased
26
Reduced
12
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
QF
QVT Financial
New York
+$4.94M
2
EAM
Eventide Asset Management
Massachusetts
+$3.73M
3
BFA
BlackRock Fund Advisors
California
+$3.31M
4
SAM
Senzar Asset Management
New York
+$3.06M
5
BI
BVF Inc
California
+$1.68M

Top Sellers

1
HM
HealthCor Management
New York
-$8.2M
2
WT
Wellcome Trust
United Kingdom
-$7.17M
3
Millennium Management
Millennium Management
New York
-$2.87M
4
ACPU
Arrowgrass Capital Partners (US)
Delaware
-$1.79M
5
SFM
Sphera Funds Management
Israel
-$1.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$29.6M +$627K +43,708 +2%
BI
2
BVF Inc
California
$19.5M +$1.68M +117,000 +10%
O
3
OrbiMed
New York
$16.7M – – –
TGHSA
4
TPG Group Holdings (SBS) Advisors
Texas
$16.4M – – –
EAM
5
Eventide Asset Management
Massachusetts
$12M +$3.73M +260,400 +51%
QF
6
QVT Financial
New York
$10M +$4.94M +344,199 +114%
Goldman Sachs
7
Goldman Sachs
New York
$7.88M +$50.2K +3,497 +0.7%
PI
8
Putnam Investments
Massachusetts
$6.91M -$46.9K -3,272 -0.7%
Franklin Resources
9
Franklin Resources
California
$6.82M – – –
BFA
10
BlackRock Fund Advisors
California
$6.58M +$3.31M +231,131 +120%
AWMDMG
11
Austin W. Marxe & David M. Greenhouse
New York
$4.67M – – –
SAM
12
Senzar Asset Management
New York
$4.07M +$3.06M +213,300 +438%
BIT
13
BlackRock Institutional Trust
California
$3.87M +$117K +8,144 +3%
Vanguard Group
14
Vanguard Group
Pennsylvania
$3.86M +$234K +16,326 +7%
State Street
15
State Street
Massachusetts
$2.68M +$1.29M +89,717 +109%
Wells Fargo
16
Wells Fargo
California
$2.36M -$29.6K -2,063 -1%
PA
17
Perceptive Advisors
New York
$2.33M – – –
RSCM
18
Rock Springs Capital Management
Maryland
$1.94M -$717K -50,000 -29%
Millennium Management
19
Millennium Management
New York
$1.68M -$2.87M -199,783 -65%
MSA
20
Mason Street Advisors
Wisconsin
$1.5M – – –
Northern Trust
21
Northern Trust
Illinois
$1.37M +$207K +14,436 +20%
Adage Capital Partners
22
Adage Capital Partners
Massachusetts
$1.36M +$1.25M +87,403 New
WMSA
23
Weiss Multi-Strategy Advisers
New York
$1.17M -$143K -10,000 -12%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$1.08M +$723K +50,426 +262%
TCIM
25
TIAA CREF Investment Management
New York
$1M +$635K +44,305 +218%
1
2 3

FPRX Hedge Fund Activity: Q2 2014 in Review

62 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q2 2014, worth a combined $177M — down 18% from $215M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new FPRX positions and 9 closed out — a net gain of 6 holders — while 26 added to existing stakes and 12 trimmed.

The largest buyer was QVT Financial, adding an estimated $4.94M. The largest seller was HealthCor Management, exiting entirely with an estimated $8.2M sold.

  • 62 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q2 2014, up from 56 in Q1 2014.
  • Funds reported $177M of Five Prime Therapeutics, Inc. stock for Q2 2014, down 18% quarter-over-quarter.
  • 15 funds opened new Five Prime Therapeutics, Inc. positions in Q2 2014 and 9 closed out, a net change of +6 holders.
  • The largest Five Prime Therapeutics, Inc. buyer in Q2 2014 was QVT Financial, an estimated $4.94M added.
  • The largest Five Prime Therapeutics, Inc. seller in Q2 2014 was HealthCor Management, an estimated $8.2M sold.

Based on aggregated 13F filings for Q2 2014.